This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Hyperion Therapeutics gets $60mm through its Series C
17 Jul 2009
Hyperion Therapeutics (developing GI and hepatic drug candidates) has raised $60mm through the closing of its Series C venture round. First-time investors Bay City Capital and Panorama Capital co-led and were joined by returning backers Highland Capital Partners, NEA, and Sofinnova Ventures. The company will use the money to study HPN100 in Phase III trials for chronic urea cycle disorders and Phase II for low-grade hepatic encephalopathy. Representatives from Bay City Capital and Panorama Capital will take seats on Hyperion's board.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?